2003, 1st ed., ISBN 9788086277318, 285
Book
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Public Health Nutrition, ISSN 1368-9800, 01/2018, Volume 21, Issue 1, pp. 5 - 17
Given evident multiple threats to food systems and supplies, food security, human health and welfare, the living and physical world and the biosphere, the...
NOVA | Ultra-processed food | Decade of Nutrition | Food processing | Sustainable Development Goals | The Anthropocene | QUALITY | DIETARY GUIDELINES | LIKELY IMPACT | DRINK PRODUCTS | OBESITY | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | NUTRITION & DIETETICS | TO-CONSUME FOOD | AVAILABILITY | INVESTMENT | PURCHASES | Food Supply | Food Handling - classification | Food Quality | Diet | Humans | United Nations | Fast Foods | Socioeconomic Factors | Health care | Additives | Salts | Seeds | Poultry | Income | Shelf life | Starches | Sustainable development | Fruits | Sustainability | Classification | Biosphere | Nutrients | Population | Malnutrition | Meals | Beverages | Public health | Sugars | Sugar | Milk | Food | Formulations | Obesity | Legumes | High income | Nutrition | Food production | Food products | Preventive medicine | International organizations | Micronutrients | Food security | Food processing industry | Dietary fiber
NOVA | Ultra-processed food | Decade of Nutrition | Food processing | Sustainable Development Goals | The Anthropocene | QUALITY | DIETARY GUIDELINES | LIKELY IMPACT | DRINK PRODUCTS | OBESITY | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | NUTRITION & DIETETICS | TO-CONSUME FOOD | AVAILABILITY | INVESTMENT | PURCHASES | Food Supply | Food Handling - classification | Food Quality | Diet | Humans | United Nations | Fast Foods | Socioeconomic Factors | Health care | Additives | Salts | Seeds | Poultry | Income | Shelf life | Starches | Sustainable development | Fruits | Sustainability | Classification | Biosphere | Nutrients | Population | Malnutrition | Meals | Beverages | Public health | Sugars | Sugar | Milk | Food | Formulations | Obesity | Legumes | High income | Nutrition | Food production | Food products | Preventive medicine | International organizations | Micronutrients | Food security | Food processing industry | Dietary fiber
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article